Skip to main content
. 2016 Jun 2;6(6):926–939. doi: 10.1016/j.stemcr.2016.05.003

Figure 1.

Figure 1

Characterization of hMSC Pro-inflammatory Secretome upon TNF-α Stimulation and TPCA-1 Treatment

(A) Fluorescence images of cytokine antibody arrays obtained via laser scanning microplate reader from multiple hMSC secretome samples.

(B) Concentration profile of hMSC secretome obtained via quantitative analysis of RayBiotech Quantibody arrays using GenePix Pro software. Of 250 cytokines, chemokines, and growth factors profiled, mediators that were statistically significant among the three hMSC samples are reported. @ refers to 1/10th of the actual concentration of ENA78. $ and NS indicate p < 0.01 and not significant between secretome from control-hMSC and TNF-hMSC, respectively; ∗ and NS indicate p < 0.01 and not significant between secretome from TNF-hMSC and TNF + TPCA-hMSC, respectively; # and NS indicate p < 0.01 and not significant between secretome from control-hMSC and TNF + TPCA-hMSC, respectively.

(C) Fold change in concentration of hMSC secretome components normalized to concentration of secretome components in TNF-hMSC. p values indicate significance (∗p < 0.01) between secretome from TNF-hMSC and TNF + TPCA-hMSC. Data represent the average of duplicates from three independent experiments from two donor MSCs. Error bars represent ± SD.